Joseph L Herring
CIK 1229873 · CEO of Covance Drug Division · last filed 2026-03-09
Joseph L Herring is a CEO of Covance Drug Division who has filed 57 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for HSIC, was dated Jun 30, 2026. Across all open-market trades the lifetime net is −$56.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions. 16 SEC filings were submitted jointly with HENRY SCHEIN INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CVD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PRINCETON, NJ 08540
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HSIC | Director | 32,281 | $85.83 | $2.77M | $127.1K | 14 | 2026-03-09 |
| TMH | Director | 2,982 | $51.86 | $154.6K | $0 | 4 | 2016-05-24 |
| LH | CEO of Covance Drug Division | 12,110 | $329.13 | $3.99M | -$4.49M | 3 | 2015-08-04 |
| COVANCE INC (CVD) Delisted | Chairman and CEO | 175,643 | — | — | -$52.38M | 34 | 2014-12-19 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-30 | HSIC | Notice (144) | −28,791 | -$2.43M | EDGAR |
| 2026-03-09 | HSIC | Grant (A) | +2,577 | $0 | EDGAR |
| 2025-03-06 | HSIC | Grant (A) | +2,844 | $0 | EDGAR |
| 2024-03-05 | HSIC | Grant (A) | +2,604 | $0 | EDGAR |
| 2023-03-03 | HSIC | Grant (A) | +2,250 | $0 | EDGAR |
| 2022-03-18 | HSIC | Grant (A) | +2,028 | $0 | EDGAR |
| 2021-03-05 | HSIC | Grant (A) | +2,790 | $0 | EDGAR |
| 2020-03-05 | HSIC | Grant (A) | +2,889 | $0 | EDGAR |
| 2019-03-06 | HSIC | Grant (A) | +2,972 | $0 | EDGAR |
| 2018-03-06 | HSIC | Grant (A) | +2,843 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.